Phaseline

Companies › Chiome Bioscience

Chiome Bioscience: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CBA-1535
T cell engager (bispecific antibody engaging 5T4 and CD3)
TRAC, 5T4Phase 1Solid TumorsDec 2026
CBA-1205
anti-DLK1 monoclonal antibody
DLK1Phase 1Solid TumorsJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07016997CBA-1535Phase 1Solid TumorsOncologyDec 2026
NCT06636435CBA-1205Phase 1Solid TumorsOncologyJun 2027

Targets

TRAC (1) 5T4 (1) DLK1 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.